89bio Net Worth
89bio Net Worth Breakdown | ETNB |
89bio Net Worth Analysis
89bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including 89bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of 89bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform 89bio's net worth analysis. One common approach is to calculate 89bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares 89bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing 89bio's net worth. This approach calculates the present value of 89bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of 89bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate 89bio's net worth. This involves comparing 89bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into 89bio's net worth relative to its peers.
Enterprise Value |
|
To determine if 89bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding 89bio's net worth research are outlined below:
| 89bio Inc had very high historical volatility over the last 90 days | |
| Net Loss for the year was (367.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| 89bio Inc currently holds about 193.34 M in cash with (367.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.16. | |
| 89bio Inc has a frail financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Disposition of 1050 shares by Le-nguyen Quoc of 89bio at 10.57 subject to Rule 16b-3 |
89bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in 89bio Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to 89bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
89bio Target Price Consensus
89bio target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. 89bio's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 9 | Strong Buy |
Most 89bio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand 89bio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of 89bio Inc, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure Valuation89bio Target Price Projection
89bio's current and average target prices are 8.47 and 30.12, respectively. The current price of 89bio is the price at which 89bio Inc is currently trading. On the other hand, 89bio's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On 89bio Target Price
Know 89bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as 89bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading 89bio Inc backward and forwards among themselves. 89bio's institutional investor refers to the entity that pools money to purchase 89bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Pictet Asset Manangement Sa | 2024-12-31 | 3 M | State Street Corp | 2024-12-31 | 2.9 M | Geode Capital Management, Llc | 2024-12-31 | 2.2 M | Redmile Group, Llc | 2024-12-31 | 2.2 M | Candriam Luxembourg S.c.a. | 2024-12-31 | 1.1 M | Alliancebernstein L.p. | 2024-12-31 | 1 M | Balyasny Asset Management Llc | 2024-12-31 | 1 M | Integral Health Asset Management, Llc | 2024-12-31 | 1000 K | Alyeska Investment Group, L.p. | 2024-12-31 | 925.4 K | Hhg Plc | 2024-12-31 | 16.5 M | Ra Capital Management, Llc | 2024-12-31 | 14.2 M |
Follow 89bio's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.24 B.Market Cap |
|
Project 89bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.77) | (0.81) | |
| Return On Capital Employed | (0.87) | (0.91) | |
| Return On Assets | (0.77) | (0.81) | |
| Return On Equity | (0.92) | (0.87) |
When accessing 89bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures 89bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of 89bio's profitability and make more informed investment decisions.
Please note, the presentation of 89bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, 89bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of 89bio's management manipulating its earnings.
Evaluate 89bio's management efficiency
89bio Inc has return on total asset (ROA) of (0.4473) % which means that it has lost $0.4473 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7834) %, meaning that it created substantial loss on money invested by shareholders. 89bio's management efficiency ratios could be used to measure how well 89bio manages its routine affairs as well as how well it operates its assets and liabilities. As of March 17, 2025, Return On Tangible Assets is expected to decline to -0.81. In addition to that, Return On Capital Employed is expected to decline to -0.91. The current year's Other Current Assets is expected to grow to about 38.3 M, whereas Total Assets are forecasted to decline to about 275.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.83 | 4.52 | |
| Tangible Book Value Per Share | 3.83 | 4.52 | |
| Enterprise Value Over EBITDA | (1.81) | (1.90) | |
| Price Book Value Ratio | 2.04 | 2.15 | |
| Enterprise Value Multiple | (1.81) | (1.90) | |
| Price Fair Value | 2.04 | 2.15 | |
| Enterprise Value | 625.2 M | 656.4 M |
Leadership effectiveness at 89bio Inc is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific 89bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on 89bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases 89bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
89bio Corporate Filings
| 3rd of March 2025 Other Reports | ViewVerify | |
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
89bio Earnings Estimation Breakdown
The calculation of 89bio's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of 89bio is estimated to be -0.5177 with the future projection ranging from a low of -0.6674 to a high of -0.41. Please be aware that this consensus of annual earnings estimates for 89bio Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.67 Lowest | Expected EPS | -0.41 Highest |
89bio Earnings Projection Consensus
Suppose the current estimates of 89bio's value are higher than the current market price of the 89bio stock. In this case, investors may conclude that 89bio is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and 89bio's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 11 | 60.25% | -1.02 | -0.5177 | -3.51 |
89bio Earnings per Share Projection vs Actual
Actual Earning per Share of 89bio refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering 89bio Inc predict the company's earnings will be in the future. The higher the earnings per share of 89bio, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.89bio Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as 89bio, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of 89bio should always be considered in relation to other companies to make a more educated investment decision.89bio Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact 89bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-26 | 2024-12-31 | -0.7594 | -1.02 | -0.2606 | 34 | ||
2024-11-06 | 2024-09-30 | -0.64 | -1.39 | -0.75 | 117 | ||
2024-08-05 | 2024-06-30 | -0.57 | -0.48 | 0.09 | 15 | ||
2024-05-09 | 2024-03-31 | -0.46 | -0.54 | -0.08 | 17 | ||
2024-02-29 | 2023-12-31 | -0.49 | -0.5 | -0.01 | 2 | ||
2023-11-08 | 2023-09-30 | -0.53 | -0.45 | 0.08 | 15 | ||
2023-08-09 | 2023-06-30 | -0.41 | -0.52 | -0.11 | 26 | ||
2023-05-04 | 2023-03-31 | -0.52 | -0.54 | -0.02 | 3 | ||
2023-03-10 | 2022-12-31 | -0.69 | -0.48 | 0.21 | 30 | ||
2022-11-10 | 2022-09-30 | -0.8 | -0.57 | 0.23 | 28 | ||
2022-08-11 | 2022-06-30 | -1.05 | -1.23 | -0.18 | 17 | ||
2022-05-11 | 2022-03-31 | -1.29 | -1.26 | 0.03 | 2 | ||
2022-03-24 | 2021-12-31 | -1.31 | -1.3 | 0.01 | 0 | ||
2021-11-11 | 2021-09-30 | -1.06 | -1.41 | -0.35 | 33 | ||
2021-08-12 | 2021-06-30 | -0.84 | -1.03 | -0.19 | 22 | ||
2021-05-12 | 2021-03-31 | -0.69 | -0.74 | -0.05 | 7 | ||
2021-03-24 | 2020-12-31 | -0.87 | -0.63 | 0.24 | 27 | ||
2020-11-10 | 2020-09-30 | -0.84 | -0.86 | -0.02 | 2 | ||
2020-08-13 | 2020-06-30 | -0.83 | -0.85 | -0.02 | 2 | ||
2020-05-13 | 2020-03-31 | -0.86 | -0.76 | 0.1 | 11 | ||
2020-03-18 | 2019-12-31 | -0.94 | -2.58 | -1.64 | 174 | ||
2019-12-18 | 2019-09-30 | -1.2 | -30.63 | -29.43 | 2452 |
89bio Corporate Management
| Harry MD | Chief Officer | Profile | |
| Francis Sarena | Chief Officer | Profile | |
| Rohan Palekar | CEO Director | Profile | |
| Quoc LeNguyen | Chief Quality | Profile | |
| Shiva CPA | Senior Officer | Profile | |
| Shiva Natarajan | Senior Officer | Profile | |
| Amanda Hill | VP Culture | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in 89bio Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 89bio. If investors know 89bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 89bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of 89bio Inc is measured differently than its book value, which is the value of 89bio that is recorded on the company's balance sheet. Investors also form their own opinion of 89bio's value that differs from its market value or its book value, called intrinsic value, which is 89bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 89bio's market value can be influenced by many factors that don't directly affect 89bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 89bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if 89bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 89bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.